[go: up one dir, main page]

AR098522A1 - Compuesto de triazolo-piridina - Google Patents

Compuesto de triazolo-piridina

Info

Publication number
AR098522A1
AR098522A1 ARP140104404A ARP140104404A AR098522A1 AR 098522 A1 AR098522 A1 AR 098522A1 AR P140104404 A ARP140104404 A AR P140104404A AR P140104404 A ARP140104404 A AR P140104404A AR 098522 A1 AR098522 A1 AR 098522A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
compound
triazolo
pyridine compound
Prior art date
Application number
ARP140104404A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR098522A1 publication Critical patent/AR098522A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente solicitud se refiere a un compuesto o una sal farmacéutica del mismo, métodos para el tratamiento de diabetes, intermediarios, y un proceso para preparar los compuestos. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque R¹ se selecciona del grupo que consiste de H y CH₃; R² se selecciona del grupo que consiste de H y CH₃; R³ se selecciona del grupo que consiste de H, alquilo C₁₋₃, O(CH₂)₃SO₂CH₃, O(CH₂)₂OCH₃, O(CH₂)₂C(CH₃)₂OH, CN, y OCF₂; o una sal del mismo farmacéuticamente aceptable. Reivindicación 13: Un compuesto intermediario de la fórmula (2) caracterizado porque R se selecciona del grupo que consiste de alquilo C₁₋₄, haloalquilo C₁₋₄, cicloalquilo C₃₋₆, alquil C₁₋₄-cicloalquilo C₃₋₆, fenilo, y alquilfenilo C₁₋₅; R⁴ se selecciona del grupo que consiste de H y CH₃; R⁵ se selecciona del grupo que consiste de H y CH₃; y R⁶ se selecciona del grupo que consiste de H, alquilo C₁₋₃, O(CH₂)₃SO₂CH₃, O(CH₂)₂OCH₃, O(CH₂)₂C(CH₃)₂OH, CN, y OCF₂; o una sal del mismo farmacéuticamente aceptable.
ARP140104404A 2013-12-13 2014-11-25 Compuesto de triazolo-piridina AR098522A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361915774P 2013-12-13 2013-12-13

Publications (1)

Publication Number Publication Date
AR098522A1 true AR098522A1 (es) 2016-06-01

Family

ID=52144909

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104404A AR098522A1 (es) 2013-12-13 2014-11-25 Compuesto de triazolo-piridina

Country Status (14)

Country Link
US (1) US9120793B2 (es)
EP (1) EP3080093B1 (es)
JP (1) JP6152227B2 (es)
KR (1) KR20160077207A (es)
CN (1) CN105814026B (es)
AR (1) AR098522A1 (es)
AU (1) AU2014364224B2 (es)
BR (1) BR112016012123A8 (es)
CA (1) CA2929317A1 (es)
EA (1) EA201690879A1 (es)
ES (1) ES2653522T3 (es)
MX (1) MX2016007567A (es)
TW (1) TW201609722A (es)
WO (1) WO2015088868A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016008910A (es) * 2014-01-10 2016-10-04 Lilly Co Eli Compuestos de fenil-triazolo-piridina.
CA2931817A1 (en) 2014-01-10 2015-07-16 Eli Lilly And Company Isopropyl triazolo pyridine compounds
US10195178B2 (en) 2016-04-11 2019-02-05 Janssen Pharmaceutica Nv GPR40 agonists in anti-diabetic drug combinations
US10106553B2 (en) 2016-04-11 2018-10-23 Janssen Pharmaceutica Nv Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
CN111712494A (zh) 2018-02-13 2020-09-25 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
BR112022017039A2 (pt) 2020-02-28 2022-11-16 Kallyope Inc Agonistas de gpr40
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ,インク. Ampkアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
WO2005066136A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Bicyclic derivatives as ppar modulators
BRPI0508098A (pt) * 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
EP2061760A1 (en) * 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
EP2310371B1 (fr) * 2008-05-26 2013-05-15 Genfit Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies
US8530413B2 (en) * 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TWI692469B (zh) * 2012-11-09 2020-05-01 南韓商Lg化學股份有限公司 Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物

Also Published As

Publication number Publication date
AU2014364224A1 (en) 2016-05-19
ES2653522T3 (es) 2018-02-07
BR112016012123A8 (pt) 2018-01-30
EP3080093B1 (en) 2017-10-04
EA201690879A1 (ru) 2016-10-31
KR20160077207A (ko) 2016-07-01
TW201609722A (zh) 2016-03-16
WO2015088868A1 (en) 2015-06-18
AU2014364224B2 (en) 2017-02-16
MX2016007567A (es) 2017-01-06
JP6152227B2 (ja) 2017-06-21
CA2929317A1 (en) 2015-06-18
US9120793B2 (en) 2015-09-01
US20150166535A1 (en) 2015-06-18
CN105814026A (zh) 2016-07-27
JP2016539984A (ja) 2016-12-22
EP3080093A1 (en) 2016-10-19
CN105814026B (zh) 2018-08-10

Similar Documents

Publication Publication Date Title
AR098522A1 (es) Compuesto de triazolo-piridina
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR103222A1 (es) Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR093937A1 (es) Compuestos quimicos
AR094668A1 (es) Amidas como moduladores de canales de sodio
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR092869A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
AR095421A1 (es) Moduladores de p2x7
AR094959A1 (es) Compuestos de imidazo piridina
AR100191A1 (es) Método para tratar adenocarcinoma de pulmón
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
AR094790A1 (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
AR102217A1 (es) Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
CU20170007A7 (es) Compuestos de imidazopiridazina
AR087868A1 (es) Compuestos de triazolopiridina como moduladores de la tirosina quinasa c-met
AR104512A1 (es) Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)
NI201800071A (es) Compuestos de isoindol
AR096160A1 (es) Inhibidores de nicotamida fosforibosiltransferasa, composiciones, productos y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure